Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Priority to CU20090039ApriorityCriticalpatent/CU20090039A7/en
Publication of CU20090039A7publicationCriticalpatent/CU20090039A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Pyridine Compounds
(AREA)
Abstract
La presente invención se refiere a 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-N-metilpiridina-2-carboxamida monohidrato, a procedimientos para su preparación, a composiciones farmacéuticas que lo comprenden y a su uso en el combate de trastornos.The present invention relates to 4- [4 - ({[4-chloro-3- (trifluoromethyl) phenyl] carbamoyl} amino) -3-fluorophenoxy] -N-methylpyridine-2-carboxamide monohydrate, to processes for its preparation, to pharmaceutical compositions that comprise it and its use in the combat of disorders.
COMPOUNDS DERIVED FROM PIRIMIDINA, INHIBITORS OF CISTEINE PROTEASA; PREPARATION PROCESSES; SALES OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF MALARIA.
Pharmaceutical composition and use of an antibody to prepare a medicament intended to inhibit the production or amplify the elimination of the P24 protein.
Cynara extract; pharmaceutical composition that contains it; and its use for the treatment of hyperglycemia, hypercholesterolemia, hypertension and hepatic steatosis.